Trials avoid high risk patients and underestimate drug harms

Summary

We are thankful to Daniel Park and Brendan Balthis for their expert research assistance. We are grateful for Christopher Manz and Hari Raman for their thoughtful guidance on how to classify oncology trials and identify trial-eligible cohorts in SEER-Medicare data. We thank David Chan and seminar participants at University of Massachusetts-Amherst for their helpful feedback on this project. Sachin Shah received grant funding from NIA K76AG074919 to support this work. The views expressed herein are those of the authors and do not necessarily reflect the views of the National Bureau of Economic Research.